An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Trial Profile

An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2016

At a glance

  • Drugs Radium 223 chloride (Primary) ; Paclitaxel
  • Indications Bone metastases; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 29 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 21 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016, according to ClinicalTrials.gov record.
    • 21 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top